Literature DB >> 6946551

Ibuprofen levels in serum and synovial fluid.

A L Mäkelä, M Lempiäinen, H Ylijoki.   

Abstract

Ibuprofen levels were measured in the serum and synovial fluid of 33 children (mean age 11 years) with juvenile chronic arthritis. A total daily dose of about 40 mg of ibuprofen per kg of body weight (mean 37.1 mg/kg) was given in three portions. In serum the peak level was reached 1-2 hours after drug intake. The half-life of elimination in serum was 2.3 +/- 0.5 hours (mean +/- 1 S.D., n = 12). Twelve hours after the last dose the mean serum level was about 20 micromol/l. Ibuprofen concentrations fluctuated far less in synovial fluid than in serum. In synovial fluid peak levels (mean 65 micromol/l) were reached 5-6 hours after drug intake. Thereafter, the levels declined slowly but 12 hours later were still higher than in serum.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6946551     DOI: 10.3109/03009748109095329

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  26 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid.

Authors:  R O Day; A J McLachlan; G G Graham; K M Williams
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 3.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

4.  In vitro activity of nonsteroidal anti-inflammatory agents, phenotiazines, and antidepressants against Brucella species.

Authors:  S Muñoz-Criado; J L Muñoz-Bellido; J A García-Rodríguez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-05       Impact factor: 3.267

5.  Evaluation of ibuprofen versus aspirin and paracetamol on efficacy and comfort in children with fever.

Authors:  E Autret; J Reboul-Marty; B Henry-Launois; C Laborde; S Courcier; J M Goehrs; G Languillat; R Launois
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 6.  Development of macromolecular prodrug for rheumatoid arthritis.

Authors:  Fang Yuan; Ling-dong Quan; Liao Cui; Steven R Goldring; Dong Wang
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

Review 7.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

8.  Pharmacokinetics of pirprofen in children with juvenile chronic arthritis.

Authors:  F Hallé; F Marfil; A Sioufi; J P Dubois; M Gioud-Paquet; G Lenoir; A M Prieur
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 9.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

10.  Pharmacokinetics of lumiracoxib in plasma and synovial fluid.

Authors:  Graham Scott; Christiane Rordorf; Christine Reynolds; Jyoti Kalbag; Michael Looby; Slavica Milosavljev; Margaret Weaver; John P Huff; Dennis A Ruff
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.